Oleg Sofrygin

1.6k total citations
47 papers, 785 citations indexed

About

Oleg Sofrygin is a scholar working on Economics and Econometrics, Genetics and Oncology. According to data from OpenAlex, Oleg Sofrygin has authored 47 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Economics and Econometrics, 8 papers in Genetics and 8 papers in Oncology. Recurrent topics in Oleg Sofrygin's work include Hemoglobinopathies and Related Disorders (7 papers), Statistical Methods and Inference (5 papers) and Cancer Treatment and Pharmacology (5 papers). Oleg Sofrygin is often cited by papers focused on Hemoglobinopathies and Related Disorders (7 papers), Statistical Methods and Inference (5 papers) and Cancer Treatment and Pharmacology (5 papers). Oleg Sofrygin collaborates with scholars based in United States, United Kingdom and Canada. Oleg Sofrygin's co-authors include Thomas E. Delea, Simu K. Thomas, Mark J. van der Laan, Pradyumna D. Phatak, Thomas D. Coates, Jean‐François Baladi, John Edelsberg, Jonathan Karnon, Gerry Oster and Kara E. Rudolph and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American Statistical Association.

In The Last Decade

Oleg Sofrygin

45 papers receiving 764 citations

Peers

Countries citing papers authored by Oleg Sofrygin

Since Specialization

Citations

This map shows the geographic impact of Oleg Sofrygin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oleg Sofrygin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oleg Sofrygin more than expected).

Fields of papers citing papers by Oleg Sofrygin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oleg Sofrygin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oleg Sofrygin. The network helps show where Oleg Sofrygin may publish in the future.

Co-authorship network of co-authors of Oleg Sofrygin

This figure shows the co-authorship network connecting the top 25 collaborators of Oleg Sofrygin. A scholar is included among the top collaborators of Oleg Sofrygin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oleg Sofrygin. Oleg Sofrygin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Automated analysis of unstructured clinical assessments improves emergency department triage performance: A retrospective deep learning analysis 2023 ·SHILAP Revista de lepidopterología ·Dana R. Sax, E. Margaret Warton, Oleg Sofrygin, Dustin G. Mark, Dustin W. Ballard, Mamata V. Kene, David R. Vinson, (unknown)	6
2	Development and Validation of a Diabetic Retinopathy Risk Stratification Algorithm 2023 ·Diabetes Care ·(unknown), Andrew J. Karter, (unknown), Howard H. Moffet, Khanh K. Thai, (unknown), Oleg Sofrygin, Ronald B. Melles	5
3	Parent-focused prevention of adolescent health risk behavior: Study protocol for a multisite cluster-randomized trial implemented in pediatric primary care 2021 ·Contemporary Clinical Trials ·(unknown), Margaret R. Kuklinski, Stacy Sterling, Richard F. Catalano, Arne Beck, Jordan M. Braciszewski, Jennifer M. Boggs, J. David Hawkins, Amy M. Loree, Constance Weisner, Susan Carey, (unknown), (unknown), (unknown), (unknown), Andrea H. Kline‐Simon, Sabrina Oesterle, Charles P. Quesenberry, Oleg Sofrygin, (unknown)	8
4	Exploiting nonsystematic covariate monitoring to broaden the scope of evidence about the causal effects of adaptive treatment strategies 2020 ·Biometrics ·Noémi Kreif, Oleg Sofrygin, Julie A. Schmittdiel, Alyce S. Adams, Richard W. Grant, Zheng Zhu, Mark J. van der Laan, Romain Neugebauer	6
5	Mediation of Neighborhood Effects on Adolescent Substance Use by the School and Peer Environments 2018 ·Epidemiology ·Kara E. Rudolph, Oleg Sofrygin, Nicole M. Schmidt, Rebecca Crowder, M. Maria Glymour, Jennifer Ahern, Theresa L. Osypuk	27
6	Robust and flexible estimation of data-dependent stochastic mediation effects: a proposed method and example in a randomized trial setting 2017 ·arXiv (Cornell University) ·Kara E. Rudolph, Oleg Sofrygin, Wenjing Zheng, Mark J. van der Laan	3
7	Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia 2017 ·Cost Effectiveness and Resource Allocation ·Anthony J. Hatswell, (unknown), (unknown), Oleg Sofrygin, Thomas E. Delea	13
8	simcausal R Package: Conducting Transparent and Reproducible Simulation Studies of Causal Effect Estimation with Complex Longitudinal Data 2017 ·Journal of Statistical Software ·Oleg Sofrygin, Mark J. van der Laan, Romain Neugebauer	20
9	Semi-Parametric Estimation and Inference for the Mean Outcome of the Single Time-Point Intervention in a Causally Connected Population 2016 ·SHILAP Revista de lepidopterología ·Oleg Sofrygin, Mark J. van der Laan	30
10	Long-term outcomes among African–American and white women with breast cancer: What is the impact of comorbidity? 2014 ·Journal of Geriatric Oncology ·Monika A. Izano, William A. Satariano, Martin C. Tammemägi, David R. Ragland, Dan H. Moore, (unknown), Arash Naeim, Mary E. Sehl, Robert A. Hiatt, Karla Kerlikowske, Oleg Sofrygin, Dejana Braithwaite	12
11	Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases 2013 ·BMC Health Services Research ·Derek Weycker, Oleg Sofrygin, (unknown), Robert G Deeter, Jason C. Legg, John Edelsberg	43
12	Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab 2011 ·The European Journal of Health Economics ·Thomas E. Delea, Paul Tappenden, Oleg Sofrygin, (unknown), Mayur M. Amonkar, Jonathan Karnon, (unknown), David Cameron	22
13	Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women With Hormone-Responsive Early Breast Cancer 2010 ·Clinical Breast Cancer ·Thomas E. Delea, Charu Taneja, Oleg Sofrygin, Satyin Kaura, Michael Gnant	10
14	Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective 2009 ·The European Journal of Health Economics ·Montserrat Vera‐Llonch, Ellen Dukes, Javier Rejas, Oleg Sofrygin, Marko A. Mychaskiw, Gerry Oster	19
15	Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq 2009 ·Vaccine ·Derek Weycker, Oleg Sofrygin, Jason E. Kemner, Stephen I. Pelton, Gerry Oster	11
16	Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria 2009 ·Journal of the American Society of Nephrology ·Thomas E. Delea, Oleg Sofrygin, James L. Palmer, Helen Lau, Veronica C. Munk, Jennifer Sung, Alan Charney, Hans‐Henrik Parving, Sean D. Sullivan	18
17	Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective 2007 ·Breast Cancer Research and Treatment ·Thomas E. Delea, (unknown), Jonathan Karnon, Oleg Sofrygin	31
18	Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate 2007 ·Lara D. Veeken ·Montserrat Vera‐Llonch, Elena Massarotti, Frederick Wolfe, Nancy A. Shadick, René Westhovens, Oleg Sofrygin, Ross Maclean, Ye Yuan, Gerry Oster	37
19	Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients 2007 ·PharmacoEconomics ·Thomas E. Delea, Oleg Sofrygin, Simu K. Thomas, Jean‐François Baladi, Pradyumna D. Phatak, Thomas D. Coates	70
20	Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer 2007 ·Clinical Breast Cancer ·Thomas E. Delea, Jonathan Karnon, Oleg Sofrygin, Simu K. Thomas, (unknown), Victoria Barghout	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact